vs

Side-by-side financial comparison of STANDARD BIOTOOLS INC. (LAB) and TERAWULF INC. (WULF). Click either name above to swap in a different company.

TERAWULF INC. is the larger business by last-quarter revenue ($26.1M vs $19.6M, roughly 1.3× STANDARD BIOTOOLS INC.). STANDARD BIOTOOLS INC. runs the higher net margin — -177.4% vs -484.2%, a 306.8% gap on every dollar of revenue. On growth, STANDARD BIOTOOLS INC. posted the faster year-over-year revenue change (-11.5% vs -25.3%). STANDARD BIOTOOLS INC. produced more free cash flow last quarter ($-23.1M vs $-1.2B). Over the past eight quarters, STANDARD BIOTOOLS INC.'s revenue compounded faster (-12.2% CAGR vs -21.5%).

Standard BioTools Inc., previously known as Fluidigm Corp., is an American life science tools company that offers analytical mass cytometry systems for flow cytometry and tissue imaging, along with associated assays and reagents, as well as an automated genomic analysis instrument and a variety of microfluidic arrays, or integrated fluidic circuits (IFCs), and consumables with fully kitted reagents. Custom assays and services are available with all systems and applications.

TeraWulf Inc. is an American bitcoin mining company. Founded in 2021 and publicly listed on Nasdaq under the ticker WULF, it operates mining facilities in New York and Pennsylvania.

LAB vs WULF — Head-to-Head

Bigger by revenue
WULF
WULF
1.3× larger
WULF
$26.1M
$19.6M
LAB
Growing faster (revenue YoY)
LAB
LAB
+13.8% gap
LAB
-11.5%
-25.3%
WULF
Higher net margin
LAB
LAB
306.8% more per $
LAB
-177.4%
-484.2%
WULF
More free cash flow
LAB
LAB
$1.2B more FCF
LAB
$-23.1M
$-1.2B
WULF
Faster 2-yr revenue CAGR
LAB
LAB
Annualised
LAB
-12.2%
-21.5%
WULF

Income Statement — Q3 FY2025 vs Q4 FY2025

Metric
LAB
LAB
WULF
WULF
Revenue
$19.6M
$26.1M
Net Profit
$-34.7M
$-126.6M
Gross Margin
48.5%
27.7%
Operating Margin
-168.5%
-330.2%
Net Margin
-177.4%
-484.2%
Revenue YoY
-11.5%
-25.3%
Net Profit YoY
-28.8%
-333.5%
EPS (diluted)
$-0.09
$-0.32

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
LAB
LAB
WULF
WULF
Q4 25
$26.1M
Q3 25
$19.6M
$50.6M
Q2 25
$21.8M
$47.6M
Q1 25
$40.8M
$34.4M
Q4 24
$35.0M
Q3 24
$22.1M
$27.1M
Q2 24
$22.5M
$35.6M
Q1 24
$45.5M
$42.4M
Net Profit
LAB
LAB
WULF
WULF
Q4 25
$-126.6M
Q3 25
$-34.7M
$-455.1M
Q2 25
$-33.5M
$-18.4M
Q1 25
$-26.0M
$-61.4M
Q4 24
$-29.2M
Q3 24
$-26.9M
$-22.7M
Q2 24
$-45.7M
$-10.9M
Q1 24
$-32.2M
$-9.6M
Gross Margin
LAB
LAB
WULF
WULF
Q4 25
27.7%
Q3 25
48.5%
57.2%
Q2 25
48.8%
53.6%
Q1 25
48.4%
28.6%
Q4 24
26.6%
Q3 24
54.9%
40.0%
Q2 24
46.1%
60.9%
Q1 24
53.1%
66.0%
Operating Margin
LAB
LAB
WULF
WULF
Q4 25
-330.2%
Q3 25
-168.5%
-48.8%
Q2 25
-118.1%
-32.7%
Q1 25
-80.8%
-173.3%
Q4 24
-147.0%
Q3 24
-120.9%
-58.1%
Q2 24
-134.5%
-19.0%
Q1 24
-132.2%
-5.5%
Net Margin
LAB
LAB
WULF
WULF
Q4 25
-484.2%
Q3 25
-177.4%
-899.7%
Q2 25
-153.7%
-38.6%
Q1 25
-63.8%
-178.5%
Q4 24
-83.5%
Q3 24
-122.0%
-84.0%
Q2 24
-203.3%
-30.6%
Q1 24
-70.6%
-22.7%
EPS (diluted)
LAB
LAB
WULF
WULF
Q4 25
$-0.32
Q3 25
$-0.09
$-1.13
Q2 25
$-0.09
$-0.05
Q1 25
$-0.07
$-0.16
Q4 24
$-0.09
Q3 24
$-0.07
$-0.06
Q2 24
$-0.12
$-0.03
Q1 24
$-0.27
$-0.03

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
LAB
LAB
WULF
WULF
Cash + ST InvestmentsLiquidity on hand
$129.4M
$3.3B
Total DebtLower is stronger
$3.1B
Stockholders' EquityBook value
$399.7M
$140.4M
Total Assets
$539.6M
$6.6B
Debt / EquityLower = less leverage
22.06×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
LAB
LAB
WULF
WULF
Q4 25
$3.3B
Q3 25
$129.4M
$711.3M
Q2 25
$158.6M
$90.0M
Q1 25
$150.9M
$218.2M
Q4 24
$274.1M
Q3 24
$210.6M
$23.9M
Q2 24
$269.8M
$104.1M
Q1 24
$287.1M
$45.8M
Total Debt
LAB
LAB
WULF
WULF
Q4 25
$3.1B
Q3 25
Q2 25
Q1 25
Q4 24
$0
Q3 24
$55.2M
$0
Q2 24
$55.1M
$72.3M
Q1 24
$55.0M
$99.4M
Stockholders' Equity
LAB
LAB
WULF
WULF
Q4 25
$140.4M
Q3 25
$399.7M
$247.3M
Q2 25
$424.5M
$174.3M
Q1 25
$454.6M
$170.4M
Q4 24
$244.4M
Q3 24
$489.3M
$372.6M
Q2 24
$510.3M
$386.2M
Q1 24
$577.3M
$272.3M
Total Assets
LAB
LAB
WULF
WULF
Q4 25
$6.6B
Q3 25
$539.6M
$2.5B
Q2 25
$557.0M
$869.4M
Q1 25
$579.6M
$841.2M
Q4 24
$787.5M
Q3 24
$681.5M
$405.9M
Q2 24
$708.7M
$479.6M
Q1 24
$777.7M
$395.4M
Debt / Equity
LAB
LAB
WULF
WULF
Q4 25
22.06×
Q3 25
Q2 25
Q1 25
Q4 24
0.00×
Q3 24
0.11×
0.00×
Q2 24
0.11×
0.19×
Q1 24
0.10×
0.37×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
LAB
LAB
WULF
WULF
Operating Cash FlowLast quarter
$-22.2M
$-123.2M
Free Cash FlowOCF − Capex
$-23.1M
$-1.2B
FCF MarginFCF / Revenue
-118.1%
-4527.0%
Capex IntensityCapex / Revenue
4.5%
4055.8%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-111.1M
$-1.7B

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
LAB
LAB
WULF
WULF
Q4 25
$-123.2M
Q3 25
$-22.2M
$-36.7M
Q2 25
$-20.7M
$-54.8M
Q1 25
$-30.3M
$56.5M
Q4 24
$-24.4M
Q3 24
$-27.9M
$-20.9M
Q2 24
$-39.0M
$16.4M
Q1 24
$-62.5M
$22.8M
Free Cash Flow
LAB
LAB
WULF
WULF
Q4 25
$-1.2B
Q3 25
$-23.1M
$-268.3M
Q2 25
$-22.6M
$-174.8M
Q1 25
$-35.3M
$-37.2M
Q4 24
$-292.4M
Q3 24
$-30.1M
$-41.7M
Q2 24
$-41.0M
$-30.2M
Q1 24
$-63.3M
$-24.1M
FCF Margin
LAB
LAB
WULF
WULF
Q4 25
-4527.0%
Q3 25
-118.1%
-530.4%
Q2 25
-103.6%
-366.8%
Q1 25
-86.6%
-108.1%
Q4 24
-835.7%
Q3 24
-136.4%
-153.9%
Q2 24
-182.2%
-84.9%
Q1 24
-138.9%
-56.9%
Capex Intensity
LAB
LAB
WULF
WULF
Q4 25
4055.8%
Q3 25
4.5%
457.8%
Q2 25
8.7%
251.8%
Q1 25
12.4%
272.3%
Q4 24
765.9%
Q3 24
10.2%
76.6%
Q2 24
8.6%
131.0%
Q1 24
1.7%
110.7%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

LAB
LAB

Consumables$8.7M45%
Services And Other Revenue$5.8M29%
Instruments$5.1M26%

WULF
WULF

Segment breakdown not available.

Related Comparisons